Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells

• Published in: International journal of molecular sciences 2022-05, Vol.23 (10), p.5536
• Main Authors: Markowski, Adam, Jaromin, Anna, Migdał, Paweł, Olczak, Ewa, Zygmunt, Adrianna, Zaremba-Czogalla, Magdalena, Pawlik, Krzysztof, Gubernator, Jerzy
• Format: Article
• Language: English
• Subjects: Acids; Addition polymerization; Adenocarcinoma; Antitumor activity; Apoptosis; Bioavailability; Biocompatibility; Biological activity; Blood vessels; Cancer therapies; Chemotherapy; Cytotoxicity; Drug delivery systems; Drugs; Dynamic stability; Erythrocytes; Glycolic acid; Homogeneity; Humans; Immune system; Intravenous administration; Lactic Acid; Lipids; Liposomes; Metastasis; Microscopy; Nanoparticles; Nanotechnology; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Particle Size; Phospholipids; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polylactide-co-glycolide; Signal transduction; Triterpenes - pharmacology; Triterpenoids; Ursolic Acid
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23105536

Despite many attempts, trials, and treatment procedures, pancreatic ductal adenocarcinoma (PDAC) still ranks among the most deadly and treatment-resistant types of cancer. Hence, there is still an urgent need to develop new molecules, drugs, and therapeutic methods against PDAC. Naturally derived compounds, such as pentacyclic terpenoids, have gained attention because of their high cytotoxic activity toward pancreatic cancer cells. Ursolic acid (UA), as an example, possesses a wide anticancer activity spectrum and can potentially be a good candidate for anti-PDAC therapy. However, due to its minimal water solubility, it is necessary to prepare an optimal nano-sized vehicle to overcome the low bioavailability issue. Poly(lactic-co-glycolic acid) (PLGA) polymeric nanocarriers seem to be an essential tool for ursolic acid delivery and can overcome the lack of biological activity observed after being incorporated within liposomes. PLGA modification, with the addition of PEGylated phospholipids forming the lipid shell around the polymeric core, can provide additional beneficial properties to the designed nanocarrier. We prepared UA-loaded hybrid PLGA/lipid nanoparticles using a nanoprecipitation method and subsequently performed an MTT cytotoxicity assay for AsPC-1 and BxPC-3 cells and determined the hemolytic effect on human erythrocytes with transmission electron microscopic (TEM) visualization of the nanoparticles and their cellular uptake. Hybrid UA-loaded lipid nanoparticles were also examined in terms of their stability, coating dynamics, and ursolic acid loading. We established innovative and repeatable preparation procedures for novel hybrid nanoparticles and obtained biologically active nanocarriers for ursolic acid with an IC50 below 20 µM, with an appropriate size for intravenous dosage (around 150 nm), high homogeneity of the sample (below 0.2), satisfactory encapsulation efficiency (up to 70%) and excellent stability. The new type of hybrid UA-PLGA nanoparticles represents a further step in the development of potentially effective PDAC therapies based on novel, biologically active, and promising triterpenoids.